PRAMLINTIDE has been studied in adults with type 1 and type 2 diabetes in clinical trials that evaluated the efficacy and safety of pramlintide plus mealtime insulin versus mealtime insulin alone. Pramlintide has been approved by the FDA for use in type 1 and type 2 diabetic patients who use insulin.
Pramlintide allows patients to use less insulin, lowers average blood sugar, and significantly reduces the rise in blood sugar that occurs in diabetics immediately after a meal.
Amylin has activity in a number of gastrointestinal and glucodynamic systems. By mimicking its activity, pramlintide acts to improve glycemic control by modulating the rate of gastric emptying, preventing postprandial increases in the hormone glucagon.
Pramlintide is used in conjunction with insulin to help lower blood sugar levels, which are especially high after meals, so pramlintide is administered with meals. The use of pramlintide does not replace daily insulin, but may reduce the amount of insulin needed, especially before meals.
